INDUSTRY NEWS
NICE GUIDANCE WELCOMED
Allergan plc has welcomed the publication of NICE guidance recommending the use of OZURDEX® (dexamethasone 0.7mg intravitreal implant in applicator) for an important group of patients with diabetic macular oedema (DME).
“This guidance from NICE confirms the value of OZURDEX® as a treatment for DME, and supports its use as a clinically relevant and cost effective option for patients with this condition,†said Sara Vincent, Senior Vice President and Allergan UK Country Manager. www.allergan.com
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.